PlainPharmaWatch

CMS Open Payments · Tool

Spineart SA vs Nevro Corp.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Spineart SA has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 775, versus 107 for the other company. Its single largest recorded recipient represents 16.9% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Spineart SA
HHI 775 · top recipient 16.9%
Ranked #1,136 of 1,838 companies by HHI
Nevro Corp.
HHI 107 · top recipient 5.5%
Ranked #1,683 of 1,838 companies by HHI

Payment Overview

Company A

Spineart SA

Total Payments
$5.1M
% of Industry
0.0%
Transactions
385
Avg per Transaction
$13.1K
Recipients
233
Avg per Recipient
$21.7K
Payment Types
3
Top Payment Type
Royalty or License
Company B

Nevro Corp.

Total Payments
$5.0M
% of Industry
0.0%
Transactions
31,030
Avg per Transaction
$161.70
Recipients
30,803
Avg per Recipient
$162.89
Payment Types
7
Top Payment Type
Food and Beverage

Highlighted values indicate the higher figure for each metric.

Total payments compared

Spineart SA vs Nevro Corp. - total reported payments in CMS Open Payments PY2024

Spineart SA$5.1MNevro Corp.$5.0M

General Payment Types Breakdown

Category shares use each company's General Payments total, not the all-tracks (General + Research + Ownership) hero figure.

Spineart SA

Royalty or License $2.0M

99.1%

Travel and Lodging $15.7K

0.8%

Food and Beverage $2.5K

0.1%

Nevro Corp.

Food and Beverage $1.1M

45.6%

Consulting Fee $527.8K

21.2%

Compensation for Faculty or Speaker (Medical Education) $486.7K

19.5%

Compensation for Services Other Than Consulting $174.4K

7.0%

Travel and Lodging $149.3K

6.0%

Grant $11.8K

0.5%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Spineart SA

  1. 1

    ALAN DANIELS

    $335,013.82 · 7 txns

  2. 2

    STACEY BEDERMAN

    $258,846.00 · 6 txns

  3. 3

    JEFFREY DECKEY

    $167,176.00 · 6 txns

  4. 4

    CONNOR TELLES

    $149,765.00 · 11 txns

  5. 5

    WARREN YU

    $117,890.30 · 6 txns

Nevro Corp.

  1. 1

    USMAN LATIF

    $136,218.38 · 167 txns

  2. 2

    ALEXANDER ESCOBAR

    $99,716.22 · 115 txns

  3. 3

    BRETT HIMMELWRIGHT

    $92,681.46 · 46 txns

  4. 4

    JASON DUNLEAVY

    $75,639.39 · 96 txns

  5. 5

    DOUGLAS BEALL

    $64,857.60 · 82 txns

Summary Comparison

Metric Spineart SA Nevro Corp.
Total Payments $5.1M $5.0M
% of Industry Total 0.0% 0.0%
Transaction Count 385 31,030
Avg per Transaction $13.1K $161.70
Recipient Count 233 30,803
Avg per Recipient $21.7K $162.89
Payment Type Count 3 7
Top Payment Type Royalty or License Food and Beverage

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.